GT Biopharma, Inc. Income Statement
GTBP|8 years of annual SEC 10-K data (FY2011-FY2020)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
GT Biopharma, Inc. reported $0 in revenue and $39M in net loss for FY2020. Revenue has grown at a 19.7% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $27.0K | $61.0K | $368.0K | $342.0K | $26.0K | $11.0K |
| Cost of Revenue | - | $0 | $0 | $57.0K | $226.0K | $94.0K | $48.0K | $65.0K |
| Gross Profit | - | $0 | $27.0K | $4.0K | $142.0K | $248.0K | -$22.0K | -$54.0K |
| SG&A Expense | $9.8M | $8.4M | $8.0M | $2.4M | $935.0K | $3.4M | $3.5M | $2.3M |
| R&D Expense | $1.7M | $975.0K | $1.0M | $0 | $0 | $0 | $17.0K | $179.0K |
| Operating Income | $16.1M | -$9.4M | -$8.9M | -$2.4M | -$793.0K | -$3.5M | -$3.9M | -$2.5M |
| Interest Expense | -$2.1M | $6.6M | $17.0M | $5.1M | $1.2M | $1.7M | $556.0K | $513.0K |
| Income Tax | - | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | -$38.6M | $9.8M | -$32.7M | -$23.5M | -$501.0K | -$5.2M | -$3.7M | -$3.0M |
| EPS (Basic) | - | $119.91 | - | - | - | - | - | - |
| EPS (Diluted) | -$0.01 | $119.91 | -$13.67 | -$0.04 | -$0.01 | -$0.01 | -$0.02 | -$0.03 |
| Shares Outstanding | 4.1M | 104.2K | 2.4M | 2.4M | 573.1M | 500.6M | 269.3M | 149.6M |
| Gross Margin | - | - | 100.0% | 6.6% | 38.6% | 72.5% | -84.6% | -490.9% |
| Operating Margin | - | - | -33063.0% | -3927.9% | -215.5% | -1027.5% | -15107.7% | -22700.0% |
| Profit Margin | - | - | -121207.4% | -38506.6% | -136.1% | -1512.0% | -14230.8% | -27227.3% |